- Spectral Medical (TSX:EDT) announced the onboarding of the Mayo Clinic in Rochester, Minnesota, as the19th clinical site for its Tigris trial
- The late-stage theranostic company is engaging a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (PMX) in a randomized controlled trial of adults being treated for endotoxemia and septic shock
- According to U.S. News & World Report, the Mayo Clinic is a premier medical centre in the United States and is top ranked in more specialties than any other hospital in the nation
- Spectral Medical Inc. last traded at $0.31 per share
Spectral Medical (TSX:EDT) announced the onboarding of the Mayo Clinic in Rochester, Minnesota, as the19th clinical site for its Tigris trial.
The late-stage theranostic company is engaging a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (PMX) in a randomized controlled trial of adults being treated for endotoxemia and septic shock.
The Toronto-based health care play is seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin. PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis. PMX is approved for therapeutic use in Japan and Europe, and has been used on more than 340,000 patients to date.
According to U.S. News & World Report, the Mayo Clinic is a premier medical centre in the United States and is top ranked in more specialties than any other hospital in the nation.
“We are making continued progress enrolling additional sites and are on track to add an additional six sites in the coming four to six weeks,” Spectral’s chief medical officer, Dr. John Kellum, said in a news release. “We remain highly encouraged by the outlook for the trial, given both the current enrollment rates and preliminary mortality data.”
Spectral develops and commercializes the treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic.
Spectral Medical Inc. last traded at $0.31 per share.
Join the discussion: Find out what everybody’s saying about this stock on the Spectral Medical Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.